



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
In the DO/EO/US

In re the Application of:

Eva-Maria PRINZENBERG et al.

Art Unit:

Application No.: 10/524,295

Examiner: Not yet assigned

371 Date: 9/29/2005

Attorney Dkt. No.: 12007-0047

For: METHOD FOR SCREENING THE ALLELIC STATE AT THE 5'-FLANKING REGION  
OF THE  $\alpha$ S1 CASEIN GENE (as amended)

**RESPONSE TO NOTIFICATION REGARDING SEQUENCE DISCLOSURES**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants request clarification for the reason for the issuance of the Notification of October 11, 2007 regarding alleged missing sequences from the CRF, a copy of which is enclosed. More particularly, the Notification alleges that the sequences found in claims 2, 11, and 21 are not found in the CRF.

Applicants dispute this contention. The sequences in question are as follows:

Primer 1 CSN1S1pro1f (5' GAA TGA ATG AAC TAG TTA CC 3'),  
Primer 2 CSN1S1pro1r (5' GAA GAA GCA GCA AGC TGG 3') and  
Primer 3 CSN1S1pro2r (5' CCT TGA AAT ATT CTA CCA G 3')

These sequences can be found in the original specification, see paragraphs [0030 and 0043] of the published application.


Moreover, the three sequences are located in the sequence listing supplied in CRF and this can be seen by the attached pages of the published application, wherein the three primers are highlighted in pink. This sequence listing shown in the published application is the same as that contained on the previously submitted CRF. To ensure that there are no questions in this regard, another CRF is submitted herewith.

In light of the above, it is submitted that the application is in compliance with 37 C.F.R. regarding submission of the sequence disclosures and acknowledgement of this fact is requested.

If there are still problems perceived by the PTO, please contact the undersigned to resolve such problems.

Applicants respectfully submit that no fee is required. However, please charge any fee deficiencies to deposit account No. 50-1088

Respectfully submitted,  
CLARK & BRODY

A handwritten signature in cursive script, appearing to read "Christopher W. Brody", written over a horizontal line.

Christopher W. Brody  
Registration No. 33,613


**Customer No. 22902**

1090 Vermont Avenue, N.W., Suite 250  
Washington DC 20005  
Telephone: 202-835-1111  
Facsimile: 202-835-1755

Docket No.: 12007-0047  
Date: December 7, 2007



UNITED STATES PATENT AND TRADEMARK OFFICE



CWB  
Page 1 of 2  
12007-0047  
DOCKETED  
Missing Parts  
Due: Dec 11, 2007  
Final: May 11, 2008

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/524,295	Eva-Maria Prinzenberg	12007-0047

INTERNATIONAL APPLICATION NO.	
PCT/DE03/02747	
I.A. FILING DATE	PRIORITY DATE
08/15/2003	08/16/2002

22902  
CLARK & BRODY  
1090 VERMONT AVENUE, NW  
SUITE 250  
WASHINGTON, DC 20005

CONFIRMATION NO. 5679

371 FORMALITIES LETTER



\*OC000000026259057\*

Date Mailed: 10/11/2007

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

DONNA S GREENE